Cue Biopharma, Inc. (CUE) vs Cartesian Therapeutics, Inc. (RNAC)

Cue Biopharma, Inc. and Cartesian Therapeutics, Inc. are both Biotechnology companies. Cue Biopharma, Inc. and Cartesian Therapeutics, Inc. are of similar size ($238.6M and $230.6M). Cue Biopharma, Inc. grew revenue faster over the last twelve months: 354.4% against −94.8%. Cartesian Therapeutics, Inc. has the higher net margin (0.00% vs −435.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Cartesian Therapeutics, Inc. leads on 9 and Cue Biopharma, Inc. on 6.

Valuation

Metric CUE RNAC Biotechnology median
P/E n/m n/m 7.88
P/S 5.29 123.01 11.47
P/B 86.22 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 4.87 75.40 10.73
Earnings yield (86.03%) (80.03%) (28.84%)
Free cash flow yield (25.17%) (36.00%) (23.03%)

Profitability

Metric CUE RNAC Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (262.03%) 0.00% 0.00%
Net margin (435.83%) 0.00% 0.00%
Free cash flow margin (133.13%) 0.00% 0.00%
Return on equity (1,603.48%) 236.88% (57.72%)
Return on assets (459.60%) (42.77%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CUE RNAC Biotechnology median
Revenue growth (TTM) 354.37% (94.81%) 5.64%
EPS growth (last fiscal year) 61.11% (11.80%) —
Revenue growth, 5-year CAGR 54.16% (29.96%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CUE RNAC Biotechnology median
Debt to equity 0.00 (0.42) 0.00
Current ratio 1.25 7.48 4.73
Net debt to EBITDA 1.10 0.89 0.96

Dividend

Metric CUE RNAC Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CUE RNAC Biotechnology median
Market cap 238.64m 230.55m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack